COST EFFECTIVENESS ANALYSIS OF THE USE OF DACLATASVIR plus ASUNAPREVIR IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PERU

被引：0
|
作者：
Sanabria, C. [1 ]
Roman, R. [2 ]
Montano, D. [3 ]
Mercado, D. [3 ]
Valenzuela, G. [3 ]
Caporale, J. E. [4 ]
机构：
[1] Univ Nacl Mayor San Marcos, Lima, Peru
[2] EsSalud, Lima, Peru
[3] BMS, San Isidro, Peru
[4] BMS, Vicente Lopez, Argentina
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2910
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN25
引用
收藏
页码：A930 / A930
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF THE USE OF DACLATASVIR plus ASUNAPREVIR IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PERU
    Sanabria, C.
    Roman, R.
    Caporale, J. E.
    Montano, D.
    Mercado, D.
    Valenzuela, G.
    VALUE IN HEALTH, 2017, 20 (09) : A928 - A928
  • [2] COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR WITH ASUNAPREVIR IN TREATMENT OF CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Babiy, V. V.
    VALUE IN HEALTH, 2016, 19 (07) : A415 - A415
  • [3] ANALYSIS OF COST EFFECTIVENESS AND COST UTILITY OF THE USE OF DACLATASVIR plus ASUNAPREVIR IN THE TREATMENT OF PATIENTS WITH HEPATITIS C IN COLOMBIA, FROM THE PERSPECTIVE OF THE THIRD PAYER
    Marrugo Pigueroa, R. D.
    Romero Prada, M. E.
    Acero Acero, G.
    Alfonso Quinones, P. A.
    VALUE IN HEALTH, 2015, 18 (07) : A871 - A871
  • [4] COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DUAL) FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN CHINA
    Cheng, W.
    Chen, W.
    VALUE IN HEALTH, 2018, 21 : S154 - S154
  • [5] ANALYSIS OF BUDGETARY IMPACT OF THE USE OF DACLATASVIR plus ASUNAPREVIR IN THE TREATMENT OF PATIENTS WITH HEPATITIS C IN COLOMBIA
    Romero Prada, M. E.
    Marrugo Figueroa, R. D.
    Acero Acero, G.
    Alfonso Quinones, P. A.
    VALUE IN HEALTH, 2015, 18 (07) : A869 - A869
  • [6] ASUNAPREVIR PLUS DACLATASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION
    Zeuli, J. D.
    Adie, S. K.
    Rizza, S. A.
    Temesgen, Z.
    DRUGS OF TODAY, 2015, 51 (11) : 629 - 643
  • [7] Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China
    Lu, Yun
    Jin, Xiuze
    Duan, Cheng-a-xin
    Chang, Feng
    PLOS ONE, 2018, 13 (04):
  • [8] Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b
    Yuchen Liu
    Zhenhua Wang
    Ruoyan Gai Tobe
    Houwen Lin
    Bin Wu
    Clinical Drug Investigation, 2018, 38 : 427 - 437
  • [9] Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b
    Liu, Yuchen
    Wang, Zhenhua
    Tobe, Ruoyan Gai
    Lin, Houwen
    Wu, Bin
    CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 427 - 437
  • [10] Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease
    Norihiko Morisawa
    Yohei Koshima
    Jun-ichi Satoh
    Yukio Maruyama
    Satoru Kuriyama
    Takashi Yokoo
    Morimasa Amemiya
    Clinical and Experimental Nephrology, 2017, 21 : 818 - 824
12345